Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?
The short, but glib, answer to the headline question posed for Viking Therapeutics (VKTX 0.11%) investors is “no,” because the likelihood is that the $4.6 billion market cap company will be bought up by a larger pharmaceutical company if it has success in its clinical trials, and particularly with its lead drug candidate VK2735. Still,…